New evidence for managing Gram-negative bloodstream infections

Keyphrases

• New Evidence 100%
• β-lactamase Inhibitor 100%
• Patient-related Outcomes 100%
• Gram-negative Bloodstream Infections 100%
• Cefiderocol 100%
• Newer β-lactams 100%
• Multidrug Resistance 50%
• Length of Stay 50%
• Gram-negative Bacteria 50%
• Bloodstream Infection 50%
• Antibiotic Susceptibility 50%
• Antibiotic Therapy 50%
• Resistance Emergence 50%
• Reduced Length 50%
• Route of Administration 50%
• Pathogen Detection 50%
• Blood Culture 50%
• Duration of Therapy 50%
• Optimal Dosing 50%
• Antimicrobial Resistance 50%
• Definitive Therapy 50%
• Appropriate Antibiotics 50%
• Mode of Resistance 50%
• Mortality Benefit 50%
• Rapid Diagnostic Test 50%
• Antimicrobial Stewardship 50%
• Antibiotic Stewardship 50%

Medicine and Dentistry

• Bloodstream Infection 100%
• Antibiotics 100%
• Beta Lactam 100%
• β-Lactamase inhibitor 100%
• Beta Lactamase Inhibitor 100%
• Cefiderocol 100%
• Antibiotic Resistance 50%
• Multidrug Resistance 50%
• Antibiotic Therapy 50%
• Treatment Duration 50%
• Antiinfective Agent 50%
• Pathogen 50%
• Gram-Negative Bacteria 50%
• Antibiogram 50%
• Blood Culture 50%
• Rapid Diagnostic Test 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Antibiotics 100%
• Bloodstream Infection 100%
• Beta Lactam 100%
• Beta Lactamase Inhibitor 100%
• Cefiderocol 100%
• Multiple Drug Resistance 50%
• Infectious Agent 50%
• Antibiotic Agent 50%
• Antiinfective Agent 50%
• Gram Negative Bacterium 50%
• Antibiotic Therapy 50%
• Antimicrobial Resistance 50%